Several drugmakers are competing to find a treatment for gout that is safer than allopurinol, the standard drug, but more affordable than Takeda Pharmaceuticals North America's Uloric, which won FDA approval in February. Savient Pharmaceuticals' Krystexxa, which is scheduled for review by an FDA panel Tuesday, is an engineered form of the uric acid enzyme uricase and has been shown in studies to melt away gout lumps faster than other medicines. Other potential gout treatments include Novartis' canakinumab and Ardea Biosciences' RDEA594, which are both in midstage studies.

Full Story:

Related Summaries